Eric Olson joined Stoke in 2024 as chief business officer, where he is responsible for overseeing business development, corporate strategy, program management and alliance management. He has more than 15 years of experience in corporate business development, strategy, and therapeutic area management at leading biopharma companies and has led or supported more than $15 billion in both buy-side and sell-side aggregate transaction value. He also has extensive experience in rare diseases, specifically with RNA science and medicines.

Prior to joining Stoke, Eric served as VP, head of Business Development at Alnylam Pharmaceuticals. Prior to Alnylam, Eric was VP, head of Rare Disease and Immunology Global Business Development at Takeda as a result of Takeda’s acquisition of Shire plc. Eric joined Shire Corporate Development in 2017 initially as head of Ophthalmology Transactions and then also assumed head of Internal Medicine Transactions in 2018. Eric began his biotech industry career in 2008 at Genzyme Corporation where he held various roles of increasing responsibility in business and corporate development, corporate venture capital, global marketing, and new product planning. He began his career in research at Yale University School of Medicine.

Eric earned a B.A. in Zoology from Connecticut College, an M.S. in Cellular & Molecular Biology from New York University, and an M.B.A. from the University of Virginia Darden School of Business.